What is the 13F Pro Quality Score for CRVO?

13F Pro ranks CervoMed Inc. (CRVO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRVO's current score at https://13fpro.ai/research/CRVO (free sign-up required for the full ranking).

Where does 13F Pro source CRVO data?

All CervoMed Inc. fundamentals and ownership data come directly from SEC EDGAR. CervoMed Inc. files with the SEC under CIK 1053691. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRVO in?

CervoMed Inc. (CRVO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CRVO research updated on 13F Pro?

CRVO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CervoMed Inc.(CRVO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1053691 CRVO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $9.7M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CRVO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CervoMed Inc. (CRVO), a Healthcare sector company. CRVO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $9.7m in revenue. Based on the latest XBRL financial filings (Q1 2026), CervoMed Inc. reports net income of $-8.0M, free cash flow of $-8.0M. Top institutional holders of CRVO by reported 13-F value include MORGAN STANLEY, VANGUARD CAPITAL MANAGEMENT, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. CRVO trades on the Nasdaq exchange and files with the SEC under CIK 1053691. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRVO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CervoMed Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-8.0M

Free Cash Flow

Q1 2026

$-8.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-43.9% YoY

$4.0MFY 2025

FY21 —FY22 $0.00FY23 $7.1MFY25 $4.0M

Net Income

-1141.8% YoY

$-27.0MFY 2025

FY21 $-24.1MFY22 $-5.8MFY23 $-2.2MFY25 $-27.0M

Operating Income

-262.2% YoY

$-28.3MFY 2025

FY21 $-24.7MFY22 $-3.5MFY23 $-7.8MFY25 $-28.3M

EPS (Diluted)

—FY 2025

FY21 $486714.75FY22 $509722.75FY23 —FY25 —

Total Assets

+129.4% YoY

$22.9MFY 2025

FY21 $37.8MFY22 $4.2MFY23 $10.0MFY25 $22.9M

Op. Cash Flow

-214.8% YoY

$-23.4MFY 2025

FY21 $-14.5MFY22 $-2.6MFY23 $-7.4MFY25 $-23.4M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2018
Revenue	$4.0M -43.9%	$7.1M	$0.00	—	—	—
Net Income	$-27.0M -1141.8%	$-2.2M +62.6%	$-5.8M +75.9%	$-24.1M -69.9%	$-14.2M +22.8%	$-18.4M
Operating Income	$-28.3M -262.2%	$-7.8M -124.8%	$-3.5M +85.9%	$-24.7M -54.5%	$-16.0M +15.7%	$-19.0M
EPS (Diluted)	—	—	$509722.75 +4.7%	$486714.75 -99.1%	$53831973.00 +1560.3%	$3242301.00
Total Assets	$22.9M +129.4%	$10.0M +139.9%	$4.2M -89.0%	$37.8M +36.5%	$27.7M +52.3%	$18.2M
Operating Cash Flow	$-23.4M -214.8%	$-7.4M -189.6%	$-2.6M +82.3%	$-14.5M -7.0%	$-13.6M -25.8%	$-10.8M

AI Insight: CRVO Financial Trends

CervoMed's revenue collapsed to zero by Q3 2025 and remains absent; equity has eroded 78% from Q2 2024 to Q1 2026.

• Revenue declined from $3M in Q2 2024 to $0M in Q3 2025, and has remained at $0M through Q1 2026.

• Equity deteriorated from $50M (Q2 2024) to $11M (Q1 2026), a cumulative loss of $39M over eight quarters.

• Operating cash burn remains steady at $6M–$8M per quarter with no revenue generation since Q2 2025.

⚠ Equity runway depleting at ~$8M per quarter; at current burn rate, capital exhaustion likely within 1–2 quarters.

⚠ No indication of revenue stabilization, product launch, or operational milestone over past eight quarters.

AI Insight: CRVO Ratio Trends

CervoMed's returns have deteriorated sharply, with ROE plunging to -177.5% in Q4 2025—the worst quarter on record.

• ROE collapsed from -56.5% in Q1 2025 to -177.5% in Q4 2025, signaling accelerating losses relative to shareholder equity.

• ROA worsened from -50.7% in Q1 2025 to -65.7% in Q2 2025, indicating deteriorating asset utilization and profitability.

⚠ Q3 2025 ROE reached -118.8%, marking inflection toward Q4's -177.5% low—no recovery visible in latest data.

⚠ TTM and OpMargin/NPM data unavailable for latest quarter; unable to assess cash generation or operational trend.

Get alerted when CRVO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CervoMed Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRVO

MORGAN STANLEY
$2.9M739,892 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.2M316,202 sh
MILLENNIUM MANAGEMENT LLC
$823.1K208,908 sh
GEODE CAPITAL MANAGEMENT, LLC
$293.1K74,371 sh
RENAISSANCE TECHNOLOGIES LLC
$251.8K63,904 sh
BlackRock, Inc.
$203.5K51,660 sh
XTX Topco Ltd
$151.6K38,487 sh
CITIZENS FINANCIAL GROUP INC/RI
$147.7K37,477 sh
VANGUARD FIDUCIARY TRUST CO
$142.4K36,151 sh
NORTHERN TRUST CORP
$118.4K30,044 sh

Fund	Value	Shares
MORGAN STANLEY	$2.9M	739,892
VANGUARD CAPITAL MANAGEMENT LLC	$1.2M	316,202
MILLENNIUM MANAGEMENT LLC	$823.1K	208,908
GEODE CAPITAL MANAGEMENT, LLC	$293.1K	74,371
RENAISSANCE TECHNOLOGIES LLC	$251.8K	63,904
BlackRock, Inc.	$203.5K	51,660
XTX Topco Ltd	$151.6K	38,487
CITIZENS FINANCIAL GROUP INC/RI	$147.7K	37,477
VANGUARD FIDUCIARY TRUST CO	$142.4K	36,151
NORTHERN TRUST CORP	$118.4K	30,044

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRVO on your watchlist

Track score changes the day CervoMed Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRVO a good stock to buy?

13F Pro's AI-powered analysis of CervoMed Inc. (CRVO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRVO are available on the CRVO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CRVO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRVO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CervoMed Inc.'s investment landscape.